KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Liabilities and Shareholders Equity (2016 - 2026)

Ionis Pharmaceuticals (IONS) has disclosed Liabilities and Shareholders Equity for 18 consecutive years, with $3.4 billion as the latest value for Q1 2026.

  • For Q1 2026, Liabilities and Shareholders Equity rose 22.65% year-over-year to $3.4 billion; the TTM value through Mar 2026 reached $13.0 billion, up 12.11%, while the annual FY2025 figure was $3.5 billion, 17.32% up from the prior year.
  • Liabilities and Shareholders Equity hit $3.4 billion in Q1 2026 for Ionis Pharmaceuticals, down from $3.5 billion in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $3.5 billion in Q4 2025 and bottomed at $2.4 billion in Q3 2022.
  • Average Liabilities and Shareholders Equity over 5 years is $2.9 billion, with a median of $2.9 billion recorded in 2023.
  • Year-over-year, Liabilities and Shareholders Equity dropped 9.42% in 2024 and then rose 22.65% in 2026.
  • Ionis Pharmaceuticals' Liabilities and Shareholders Equity stood at $2.5 billion in 2022, then increased by 18.0% to $3.0 billion in 2023, then grew by 0.45% to $3.0 billion in 2024, then grew by 17.32% to $3.5 billion in 2025, then decreased by 2.1% to $3.4 billion in 2026.
  • According to Business Quant data, Liabilities and Shareholders Equity over the past three periods came in at $3.4 billion, $3.5 billion, and $3.0 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.